The healthcare sector has been severely impacted by the coronavirus (COVID-19) outbreak. Industry associations, governments, and medical institutes are imposing travel restrictions, and as a result, some scheduled meetings and conferences face postponement or cancellation. The spread of COVID-19 has forced organizations to rethink their plans. HCPs are already at a higher risk of COVID-19 […]

PD-1 inhibitors have become a mainstay of treatment for many cancers in recent years. However, while these agents are associated with a robust response in some patients, the majority of patients will progress. Several trials have evaluated potential combination strategies to bolster responses to PD-1 inhibitors, but there is no clear consensus in this area. […]

According to an analysis of the PREVAIL and AFFIRM clinical trials, development of new bone lesions in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) who are stable or responding to enzalutamide is a form of pseudoprogression that does not necessarily impact long-term outcomes. The study evaluated outcomes in 1672 patients treated with enzalutamide on […]

Each year the American Society of Clinical Oncology (ASCO) releases a report highlighting the greatest clinical advances in cancer research and treatment for the past year. In the most recent report, released in early February, ASCO president Howard “Skip” Burris III, MD, named the refinement of surgical treatment of cancer as the Advance of the […]

The major news in recent months has been the emergence and spread of a novel coronavirus, COVID-19 (formerly known as 2019nCoV). To help clinicians sort fact from fiction regarding this new virus and infection, a primer was recently published in JAMA. This provides background on the origin and spread of COVID-19, common signs and symptoms […]